Best Cardiac and Vascular Disorders Companies in Tel Aviv, Israel
The 36 best Cardiac and Vascular Disorders companies in Tel Aviv, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MValve Technologies.
Ranked: Best Cardiac and Vascular Disorders companies in Tel Aviv
| # | Company | Employees | Disclosed funding | Last round | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Medinol Coronary stenting system | 400 | — | — | Judith Richter Co-Founder & CEO | WordPressMySQLPHP+16 | Acquired | 506 patents Minimally invasive vascular devices: crimpable helical stents and retractable-sleeve catheters. | — |
| 2 | Vectorious Medical Tech Implant for left-atrial monitoring | 69 | $14M | 77 mo ago | — | WordPressMySQLPHP+20 | Acquired | — | — |
| 3 | cardiovalve Developer of a novel transcatheter valve replacement system for mitral and tricuspid valve replacement. | 47 | — | — | Amir Gross CEO | — | Acquired | 315 patents Implantable prosthetic heart valves and minimally invasive delivery/anchoring systems | — |
| 4 | Valtech Portfolio of valve repair and replacement solutions | 40 | $48M | 127 mo ago | — | — | Acquired | — | — |
| 5 | Endospan Provider of stent graft endovascular solution for aortic aneurysms | 40 | $25M | 130 mo ago | — | WixSentrySalesforce+11 | Acquired | 226 patents Patents concentrated in health & consumer products | — |
| 6 | Valcare Medical Developer of minimally-invasive technologies for mitral regurgitation treatment and repair | 30 | $28M | 96 mo ago | Steve Sandweg Chief Executive Officer | WordPressMySQLPHP+21 | Series B | — | — |
| 7 | Vascular Graft Solutions External support technology to improve vein graft longevity and improve outcome of Cardiac bypass surgery. | 24 | $11M | 140 mo ago | — | — | Series B | 53 patents External support devices and sheaths for surgical vascular anastomosis and graft stabilization | — |
| 8 | MValve Technologies Stealth startup focused on Mitral Regurgitation solutions | 13 | $215M | 131 mo ago | — | — | Acqui-Hired | 29 patents Transcatheter cardiac valve implantation support structures and delivery systems. | — |
| 9 | Append Medical Developer of a device for the left atrial appendage closure system | 10 | $12M | 38 mo ago | — | WordPressMySQLPHP+12 | Series A | — | — |
| 10 | Restore Medical Catheter-delivered implant for treatment of congestive heart failure 42Growth top 30%Patents top 38%Funding top 40%News top 40% All 8 signals ▾Growthtop 30% Patentstop 38% Fundingtop 40% Newstop 40% Innovationtop 44% Moattop 47% Globalbottom 35% Marketbottom 29% Growth: Fresh capital in last 24 mo Patents: 30 patents matched (strict assignee match) · 20 filings since 2022 vs 10 in 2017-21 rank vs industry peers · Fliar Intelligence Index 42/100 | 9 | $9M | 14 mo ago | — | — | Series B | 30 patents Implantable vascular constriction devices for lumenal surfaces, e.g., pulmonary artery implants. | — |
| 11 | CardioVia Developer of a minimally invasive device for accessing pericardial space | 9 | $56K | 88 mo ago | Yonatan Demma Co-Founder | WixSentryBootstrap+11 | Funding Raised | 8 patents Non-penetrating cardiac tissue separation devices for minimally invasive heart surgery | — |
| 12 | omnysense Digital-Health; a ''smart'' thermometer device & system that performs a checkup in 30 seconds, analyze the… | 8 | — | — | — | — | Private | 14 patents Oral health monitoring devices for respiratory sound and ECG measurement | — |
| 13 | Revamp Medical Catheter-based solution for acute decompensated heart failure (ADHF) | 6 | $113K | 39 mo ago | Lihu Avitov Co-Founder | — | Series A | — | — |
| 14 | VeinWay Developer of a device to treat chronic venous diseases | 6 | — | 36 mo ago | Jordan Pollack Co-Founder & CEO | — | Seed | 10 patents Minimally invasive vascular access devices for bypassing or treating blocked blood vessels. | — |
| 15 | EndoWays Developer of robotic-assisted microcatheter | 5 | $750K | — | Noam Shamay Founder & CEO | — | Acqui-Hired | 14 patents Variable-stiffness catheters and remote-controlled injection systems for minimally invasive procedures. | — |
| 16 | FlexiCath Touch-free indwelling midline catheter | — | $4M | 213 mo ago | Shai Amisar Co-Founder & CEO | — | Series A | 27 patents Removable adapters and insertion devices for split catheter introducers in vascular procedures | — |
| 17 | BSP Medical Developer of ECG devices for Ischemic heart disease | — | $2M | 124 mo ago | Amir Beker Founder | — | Public | — | — |
Top 12 Cardiac and Vascular Disorders companies in Tel Aviv
#1
Series B · Tel Aviv, Tel Aviv · founded 2016 · 9 employees$9Mraised▾
Restore Medical is an early stage company focussed on developing a catheter-delivered implant for treatment of congestive heart failure (CHF). It is developing its flagship product called ContraBand which claims to provide improved quality of life for patients with left ventricle heart failure. As of December 2016, the company is operating as a portfolio of Incentive & the hasn't disclosed the device development details.
- Jul 2025Series B$23M
- Jun 2022Grant (prize money)$2.6M
#2
Series A · Or Yehuda, Tel Aviv · founded 2016 · 10 employees$11.8Mraised▾
Developer of a device for the left atrial appendage closure system. The system is used to prevent the blood clot leakage from the Left Atrial Appendage through LAA complete closure.
- Jul 2023Series A$4.3M
- Aug 2021Series A$7.4M
#3
Acqui-Hired · Herzliya, Tel Aviv · founded 2012 · 13 employees$215Mraised▾
MValve Technologies is an Israeli-Americal company focused on developing solutions for Mitral Regurgitation (MR). MR is an abnormal reversal of blood flow from the heart's left ventricle into the left atrium. The company's product is a docking system for transcatheter mitral valve repair which works in conjunction with Boston Scientific's Lotus Valve. MValve has been backed by Boston Scientific since 2012. The $15 M deal with Boston Scientific in 2014 included a $200 M buyout option. In Oct 2015, the company announced the first human implantation of its device in a patient in Germany. Lotus Valve System has not received FDA approval as of Oct, 2015. It is CE marked.
- Oct 2015Series C$200M
- Jul 2014Series A$15M
#4
Acquired · Tel Aviv, Tel Aviv · founded 2011 · 69 employees$14.3Mraised▾
Vectorious Medtech developed an miniature, wireless sensory implant that enables the hemodynamic monitoring of left atrial pressure for accurate, daily physiological indication and optimized Congestive Heart Failure (CHF) patient management. The miniature sensory implant is delivered via a minimally invasive procedure enables low risk delivery. A convenient 'push button' data acquisition and transmission system encourages daily patient compliance and long-term physician monitoring.
- Mar 2020Grant (prize money)$55.3K
- Jul 2018Series B$2M
- Apr 2018Grant (prize money)$2.3M
- Mar 2018Grant (prize money)$2.2M
#5
Acquired · Or Yehuda, Tel Aviv · founded 2006 · 40 employees$47.8Mraised▾
Valtech offers a portfolio of products for mitral valve and tricuspid valve repair & replacement. Flagship solution Cardioband is a percutaneous annuloplasty solution. Other products are Cardiovalve (valve replacement system) and Cardian (annuloplasty ring system). In November 2016, Edward LifeSciences acquired Valtech for $340M in stock & up to $350M in additional pre-specified milestone-driven payments over the next 10 years.
- Jan 2016Series C$30M
- Feb 2010Series B$17.8M
#6
Series B · Herzliya, Tel Aviv · founded 2012 · 30 employees$28Mraised▾
Developer of minimally-invasive technologies for mitral regurgitation treatment and repair. The company focuses on a mitral valve treatment platform based on a D-shaped ring. This ring serves as a tool for mitral annulus repair. It also functions as a docking station for future technology. The company's management team includes experts in sales, finance, and cardiovascular devices.
- Sep 2018Series B$20M
- Jul 2012Series A$8M
#7
Acquired · Herzliya, Tel Aviv · founded 2009 · 40 employees$25Mraised▾
EndoSpan is a VC backed pre-clinical stage medical device start-up developing an endovascular system for endovascular aortic aneurysm repair. The Nexus platform helps in optimizing the open-heart surgery to minimally invasive procedures by giving real-time insights on the aortic conditions. It has two stent graft systems - Horizon, and Nexus. Both products are in clinical development.
- Oct 2015Series C$10M
- Series B$15M
#8
Series B · Tel Aviv, Tel Aviv · founded 2009 · 24 employees$10.7Mraised▾
Vascular Graft Solutions develops and commercialises devices to improve the outcome of cardiac bypass surgery. The company product, the VEST (Venous External Scaffolding Technology), is a external mechanical support for autologous vein grafts that is designed to improve vein graft longevity. VEST recieved CE approval in 2014 and is commercially available in selected international markets including UK, Germany, Italy, Belgium, Israel, Switzerland, Greece and South Africa. As of June 2016, additional post marketing studies in Europe are ongoing, to establish the role of SVG external stenting in improving CABG outcome.
- Jan 2015Series B$6.2M
- Feb 2014Series A$2M
- Feb 2012Series A$1M
- Jan 2011Series A$1.5M
#9
Series A · Tel Aviv, Tel Aviv · founded 2007$3.6Mraised▾
The M/29 is the a touch-free indwelling midline catheter that can be placed in under 10 minutes following minimal training. The company claims that it is the only catheter in the world that eliminates airborne or touch contamination by design, furthermore, that it offers the simplicity of a PIV, and the advantages of a Midline catheter. The M/29 is FDA cleared for 29 days of indwelling use.
- Dec 2008Series A$600K
- Jan 2007Series A$3M
#10
Series A · Tel Aviv, Tel Aviv · founded 2016 · 6 employees$113.1Kraised▾
Catheter-based solution for acute decompensated heart failure (ADHF). It is an early-stage medical device company focused on developing solutions for cardiovascular disorders. It is the first to develop a catheter-based solution for the treatment of Acute Decompensated Heart Failure (ADHF). As of November 2016, the company hasn't disclosed its product development details.
- May 2023Series A—
- Apr 2019Grant (prize money)$55.8K
- Jan 2019Grant (prize money)$57.3K
#11
Public · Tel Aviv, Tel Aviv · founded 2006$2.5Mraised▾
Developer of ECG devices for Ischemic heart disease. The company uses proprietary signal processing technology that is a suite of algorithms, implemented in software, and enables early detection of coronary artery disease and ischemia. Its products analyze high-frequency QRS components for more sensitive and accurate results than conventional stress testing. It is also integrated with both its resting stress ECG testing systems.
- Apr 2016Grant (prize money)$57K
- Jun 2008Series A$2.5M
#12
Acqui-Hired · Or Yehuda, Tel Aviv · founded 2017 · 5 employees$750Kraised▾
Endoways has developed a robotic-assisted microcatheter for blood vessel navigation. The robotic-assisted disposable microcatheter is used for minimally invasive vascular system navigation that uses patient bed-side propulsion with the wireless steering system for the navigation. The company claims that it can be used for radiology procedures such as liver embolization, BPH, neuroradiology and many others.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.